See all M&A in Orthopedics here
Bioventus Enters Into Definitive Agreement to Divest BMP Development Program to Viscogliosi Brothers, LLC (press release)
Bioventus, a global leader in orthobiologic solutions, has entered into a definitive agreement to divest its next generation bone morphogenetic protein (BMP) development program to a new company formed by Viscogliosi Brothers, LLC (VB), a private equity investment firm focused on developing innovative neuromusculoskeletal technologies.
Bioventus acquired the exclusive, worldwide license to the BMP portfolio of development programs and associated intellectual property from Pfizer, Inc., in 2013. [HISTORY - 2013 Bioventus acquires BMP-2 for soft tissue applications ]. The portfolio, which will now be sold to VB, includes the next-generation BMP in development, as well as a BMP program for soft tissue indications.
The transaction is expected to close in late Q3 and is conditional on VB having raised the requisite funds to complete the sale. When completed, Bioventus will receive an equity stake in the new company formed by Viscogliosi Brothers that will work on the BMP program. In addition, Bioventus will have an observat...
